1. Home
  2. Pharma & Healthcare
  3. Global Biologics and Biosimilars Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027

Global Biologics and Biosimilars Industry Outlook 2021: Overview, Opportunities, Key Companies and Forecast to 2027

Publication Month: Sep 2021 | No. of Pages: 145 Published By: GRD Survey
Single User License: US $ 3980
Corporate User License: US $ 7960

Executive Summary

According to GRD Survey data, the global Biologics and Biosimilars market was valued at million US$ in 2020 and is expected to reach million US$ by the end of 2027, growing at a CAGR of % in the forecast period 2021 and 2027.

This report studies the Biologics and Biosimilars market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Biologics and Biosimilars in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

Market Snapshot, By Product Type
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others

Market Snapshot, By Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Others

Market Snapshot, By Region:
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
South Africa
Israel
Turkey
Saudi Arabia

Main Market Players Analyzed in this report, including:
Sanofi-Aventis
Roche
Pfizer
Novo Nordisk
Novartis
Merck
Johnson & Johnson
Innovent
Gelgen
Ganlee
Eli Lilly
Dong Bao
CP Guojian
Changchun High Tech
Biotech
Amgen
AbbVie
3sbio

The study objectives of this report are:
To study and analyze the global Biologics and Biosimilars market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Biologics and Biosimilars market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Biologics and Biosimilars manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Biologics and Biosimilars market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Biologics and Biosimilars submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Biologics and Biosimilars are as follows:
History Year: 2016-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2027

This report includes the estimation of market size in terms of value (million USD) and volume from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders Considered in the study:
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries

Table of Contents

1 Market Definition & Scope
1.1 Definition & Scope
1.2 Biologics and Biosimilars Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Biologics and Biosimilars Market Performance and Outlook

2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter's Five Forces Analysis
2.3 Comparison of Alternatives and Biologics and Biosimilars

3 Supply Chain and Manufacturing Cost Analysis
3.1 Supply Chain Analysis
3.2 Raw Materials and Key Suppliers Analysis
3.2.1 Raw Materials Introduction
3.2.1 Raw Materials Key Suppliers List
3.3 Biologics and Biosimilars Sales Channel and Distributors Analysis
3.3.1 Biologics and Biosimilars Sales Channel
3.3.2 Biologics and Biosimilars Distributors
3.4 Key Buying Industries/Consumers
3.4.1 Major Buyers in Application One
3.4.2 Major Buyers in Application Two
3.4.1 Major Buyers in Application Three
3.5 Biologics and Biosimilars Manufacturing Cost Structure Analysis

4 Market Segment: by Type
4.1 Biologics and Biosimilars Type Introduction
4.1.1 Monoclonal Antibodies
4.1.2 Interferon
4.1.3 Erythropoietin
4.1.4 Insulin
4.1.5 Vaccines
4.1.6 Others
4.2 Global Biologics and Biosimilars Sales by Type 2016-2021
4.3 Global Biologics and Biosimilars Revenue by Type 2016-2021
4.4 Global Biologics and Biosimilars Price by Type 2016-2021

5 Market Segment: by Application
5.1 Biologics and Biosimilars Type Introduction
5.1.1 Tumor
5.1.2 Diabetes
5.1.3 Cardiovascular
5.1.3 Hemophilia
5.1.4 Others
5.2 Global Biologics and Biosimilars Sales by Application 2016-2021
5.3 Global Biologics and Biosimilars Revenue by Application 2016-2021
5.4 Global Biologics and Biosimilars Price by Application 2016-2021

6 Marke Segment: by Region
6.1 Global Biologics and Biosimilars Market by Region
6.1.1 Global Biologics and Biosimilars Sales by Regions
6.1.2 Global Biologics and Biosimilars Revenue by Regions
6.2 North America Biologics and Biosimilars Market 2016-2021
6.3 Europe Biologics and Biosimilars Market 2016-2021
6.4 Asia Pacific Biologics and Biosimilars Market 2016-2021
6.5 South America Biologics and Biosimilars Market 2016-2021
6.6 Middle East and Africa Biologics and Biosimilars Market 2016-2021

7 North America
7.1 North America Biologics and Biosimilars Market by Country 2016-2021
7.1.1 North America Biologics and Biosimilars Sales by Country
7.1.2 North America Biologics and Biosimilars Revenue by Country
7.2 United States
7.3 Canada
7.4 Mexico

8 Europe
8.1 Europe Biologics and Biosimilars Market by Country 2016-2021
8.1.1 Europe Biologics and Biosimilars Sales by Country
8.1.2 Europe Biologics and Biosimilars Revenue by Country
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain

9 Asia Pacific
9.1 Asia Pacific Biologics and Biosimilars Market by Country 2016-2021
9.1.1 Asia Pacific Biologics and Biosimilars Sales by Country
9.1.2 Asia Pacific Biologics and Biosimilars Revenue by Country
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia

10 South America
10.1 South America Biologics and Biosimilars Market by Country 2016-2021
10.1.1 South America Biologics and Biosimilars Sales by Country
10.1.2 South America Biologics and Biosimilars Revenue by Country
10.2 Brazil
10.3 Argentina
10.4 Colombia

11 Middle East and Africa
11.1 Middle East and Africa Biologics and Biosimilars Market by Country 2016-2021
11.1.1 Middle East and Africa Biologics and Biosimilars Sales by Country
11.1.2 Middle East and Africa Biologics and Biosimilars Revenue by Country
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa

12 Key Participants Company Information
12.1 Sanofi-Aventis
12.1.1 Sanofi-Aventis Company Information
12.1.2 Sanofi-Aventis Biologics and Biosimilars Product Portfolio, Specification and Application
12.1.3 Sanofi-Aventis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.1.4 Sanofi-Aventis Key Development
12.2 Roche
12.2.1 Roche Company Information
12.2.2 Roche Biologics and Biosimilars Product Portfolio, Specification and Application
12.2.3 Roche Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.2.4 Roche Key Development
12.3 Pfizer
12.3.1 Pfizer Company Information
12.3.2 Pfizer Biologics and Biosimilars Product Portfolio, Specification and Application
12.3.3 Pfizer Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.3.4 Pfizer Key Development
12.4 Novo Nordisk
12.4.1 Novo Nordisk Company Information
12.4.2 Novo Nordisk Biologics and Biosimilars Product Portfolio, Specification and Application
12.4.3 Novo Nordisk Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.4.4 Novo Nordisk Key Development
12.5 Novartis
12.5.1 Novartis Company Information
12.5.2 Novartis Biologics and Biosimilars Product Portfolio, Specification and Application
12.5.3 Novartis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.5.4 Novartis Key Development
12.6 Merck
12.6.1 Merck Company Information
12.6.2 Merck Biologics and Biosimilars Product Portfolio, Specification and Application
12.6.3 Merck Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.6.4 Merck Key Development
12.7 Johnson & Johnson
12.7.1 Johnson & Johnson Company Information
12.7.2 Johnson & Johnson Biologics and Biosimilars Product Portfolio, Specification and Application
12.7.3 Johnson & Johnson Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.7.4 Merck Key Development
12.9 Gelgen
12.9.1 Gelgen Company Information
12.9.2 Gelgen Biologics and Biosimilars Product Portfolio, Specification and Application
12.9.3 Gelgen Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.9.4 Gelgen Key Development
12.8 Innovent
12.8.1 Innovent Company Information
12.8.2 Innovent Biologics and Biosimilars Product Portfolio, Specification and Application
12.8.3 Innovent Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.8.4 Innovent Key Development
12.11 Eli Lilly
12.11.1 Eli Lilly Company Information
12.11.2 Eli Lilly Biologics and Biosimilars Product Portfolio, Specification and Application
12.11.3 Eli Lilly Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.11.4 Eli Lilly Key Development
12.12 Dong Bao
12.12.1 Dong Bao Company Information
12.12.2 Dong Bao Biologics and Biosimilars Product Portfolio, Specification and Application
12.12.3 Dong Bao Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.12.4 Dong Bao Key Development
12.13 CP Guojian
12.13.1 CP Guojian Company Information
12.13.2 CP Guojian Biologics and Biosimilars Product Portfolio, Specification and Application
12.13.3 CP Guojian Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.13.4 CP Guojian Key Development
12.14 Changchun High Tech
12.14.1 Changchun High Tech Company Information
12.14.2 Changchun High Tech Biologics and Biosimilars Product Portfolio, Specification and Application
12.14.3 Changchun High Tech Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.14.4 Changchun High Tech Key Development
12.15 Biotech
12.15.1 Biotech Company Information
12.15.2 Biotech Biologics and Biosimilars Product Portfolio, Specification and Application
12.15.3 Biotech Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
12.15.4 Biotech Key Development
12.17 AbbVie
12.18 3sbio

13 Global Biologics and Biosimilars Market Forecast by Region by Type and by Application
13.1 Global Biologics and Biosimilars Sales, Revenue Forecast 2022-2027
13.2 Global Biologics and Biosimilars Forecast by Regions
13.2.1 Global Biologics and Biosimilars Sales Forecast by Region 2022-2027
13.2.2 Global Biologics and Biosimilars Revenue Forecast by Region 2022-2027
13.3 Global Biologics and Biosimilars Forecast by Type
13.3.1 Global Biologics and Biosimilars Sales Forecast by Type 2022-2027
13.3.2 Global Biologics and Biosimilars Revenue Forecast by Type 2022-2027
13.3.3 Global Biologics and Biosimilars Price Forecast by Type 2022-2027
13.4 Global Biologics and Biosimilars Forecast by Application
13.4.1 Global Biologics and Biosimilars Sales Forecast by Application 2022-2027
13.4.2 Global Biologics and Biosimilars Revenue Forecast by Application 2022-2027
13.4.3 Global Biologics and Biosimilars Price Forecast by Application 2022-2027

14 Analyst Views and Conclusions
15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer


List of Tables

Table 1: Global Biologics and Biosimilars Production Specifications
Table 2: Drivers in Biologics and Biosimilars Market
Table 3: Restraints Biologics and Biosimilars Market
Table 4: Opportunity in Biologics and Biosimilars Market
Table 5: Comparion of Alternative and Biologics and Biosimilars
Table 6: Biologics and Biosimilars Raw Materials Key Suppliers List
Table 7: Biologics and Biosimilars Distributors List
Table 8: Biologics and Biosimilars Major Buyers in Application One
Table 9: Biologics and Biosimilars Major Buyers in Application Two
Table 10: Biologics and Biosimilars Major Buyers in Application Three
Table 11: Global Biologics and Biosimilars Sales (K Units) by Type 2016-2021
Table 12: Global Biologics and Biosimilars Sales Market Share by Type 2016-2021
Table 13: Global Biologics and Biosimilars Revenue (Million USD) by Type 2016-2021
Table 14: Global Biologics and Biosimilars Revenue Market Share by Type 2016-2021
Table 15: Global Biologics and Biosimilars Price by Type 2016-2021
Table 16: Global Biologics and Biosimilars Sales (K Units) by Application 2016-2021
Table 17: Global Biologics and Biosimilars Sales Market Share by Application 2016-2021
Table 18: Global Biologics and Biosimilars Revenue (Million USD) by Application 2016-2021
Table 19: Global Biologics and Biosimilars Revenue Market Share by Application 2016-2021
Table 20: Global Biologics and Biosimilars Price by Application 2016-2021
Table 21: Global Biologics and Biosimilars Sales (K Units) by Region 2016-2021
Table 22: Global Biologics and Biosimilars Sales Market Share by Region 2016-2021
Table 23: Global Biologics and Biosimilars Revenue (Million USD) by Region 2016-2021
Table 24: Global Biologics and Biosimilars Revenue Market Share by Region 2016-2021
Table 25: North America Biologics and Biosimilars Sales (K Units) by Country 2016-2021
Table 26: North America Biologics and Biosimilars Sales Market Share by Country 2016-2021
Table 27: North America Biologics and Biosimilars Revenue (Million USD) by Country 2016-2021
Table 28: North America Biologics and Biosimilars Revenue Market Share by Country 2016-2021)
Table 29: Europe Biologics and Biosimilars Sales (K Units) by Country 2016-2021
Table 30: Europe Biologics and Biosimilars Sales Market Share by Country 2016-2021
Table 31: Europe Biologics and Biosimilars Revenue (Million USD) by Country 2016-2021
Table 32: Europe Biologics and Biosimilars Revenue Market Share by Country 2016-2021)
Table 33: Asia Pacific Biologics and Biosimilars Sales (K Units) by Country 2016-2021
Table 34: Asia Pacific Biologics and Biosimilars Sales Market Share by Country 2016-2021
Table 35: Asia Pacific Biologics and Biosimilars Revenue (Million USD) by Country 2016-2021
Table 36: Asia Pacific Biologics and Biosimilars Revenue Market Share by Country 2016-2021)
Table 37: South America Biologics and Biosimilars Sales (K Units) by Country 2016-2021
Table 38: South America Biologics and Biosimilars Sales Market Share by Country 2016-2021
Table 39: South America Biologics and Biosimilars Revenue (Million USD) by Country 2016-2021
Table 40: South America Biologics and Biosimilars Revenue Market Share by Country 2016-2021)
Table 41: Middle East and Africa Biologics and Biosimilars Sales (K Units) by Country 2016-2021
Table 42: Middle East and Africa Biologics and Biosimilars Sales Market Share by Country 2016-2021
Table 43: Middle East and Africa Biologics and Biosimilars Revenue (Million USD) by Country 2016-2021
Table 44: Middle East and Africa Biologics and Biosimilars Revenue Market Share by Country 2016-2021)
Table 45 Sanofi-Aventis Company Information
Table 46 Sanofi-Aventis Biologics and Biosimilars Product Portfolio, Specification and Application
Table 47 Sanofi-Aventis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
Table 48 Roche Company Information
Table 49 Roche Biologics and Biosimilars Product Portfolio, Specification and Application
Table 50 Roche Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
Table 51 Pfizer Company Information
Table 52 Pfizer Biologics and Biosimilars Product Portfolio, Specification and Application
Table 53 Pfizer Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
Table 54 Novo Nordisk Company Information
Table 55 Novo Nordisk Biologics and Biosimilars Product Portfolio, Specification and Application
Table 56 Novo Nordisk Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
Table 57 Novartis Company Information
Table 58 Novartis Biologics and Biosimilars Product Portfolio, Specification and Application
Table 59 Novartis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
Table 60 Merck Company Information
Table 61 Merck Biologics and Biosimilars Product Portfolio, Specification and Application
Table 62 Merck Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
Table 63 Johnson & Johnson Company Information
Table 64 Johnson & Johnson Biologics and Biosimilars Product Portfolio, Specification and Application
Table 65 Johnson & Johnson Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
Table 66 Innovent Company Information
Table 67 Innovent Biologics and Biosimilars Product Portfolio, Specification and Application
Table 68 Innovent Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
Table 69 Gelgen Company Information
Table 70 Gelgen Biologics and Biosimilars Product Portfolio, Specification and Application
Table 71 Gelgen Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2021)
Table 72: Global Biologics and Biosimilars Sales (K Units) Forecast by Region (2022-2027)
Table 73: Global Biologics and Biosimilars Sales Market Share Forecast by Region (2012-2027)
Table 74: Global Biologics and Biosimilars Revenue (Million USD) Forecast by Region (2022-2027)
Table 75: Global Biologics and Biosimilars Revenue Market Share Forecast by Region (2022-2027)
Table 76: Global Biologics and Biosimilars Sales (K Units) Forecast by Type (2022-2027)
Table 77: Global Biologics and Biosimilars Sales Market Share Forecast by Type (2012-2027)
Table 78: Global Biologics and Biosimilars Revenue (Million USD) Forecast by Type (2022-2027)
Table 79: Global Biologics and Biosimilars Revenue Market Share Forecast by Type (2022-2027)
Table 80: Global Biologics and Biosimilars Sales (K Units) Forecast by Applicaion (2022-2027)
Table 81: Global Biologics and Biosimilars Sales Market Share Forecast by Application (2012-2027)
Table 82: Global Biologics and Biosimilars Revenue (Million USD) Forecast by Application (2022-2027)
Table 83: Global Biologics and Biosimilars Revenue Market Share Forecast by Application (2022-2027)

Tables and Figures

List of Figures

Figure 1: Biologics and Biosimilars Picture
Figure 2: Global Biologics and Biosimilars Market Size (Million USD) and Growth Rate (2016-2027)
Figure 3: Porter's Five Forces Analysis
Figure 4: Biologics and Biosimilars Supply Chain Analysis
Figure 5: Biologics and Biosimilars Manufacturing Cost Structure Analysis
Figure 6: Product Picture of Monoclonal Antibodies
Figure 7: Product Picture of Interferon
Figure 8: Global Biologics and Biosimilars Sales Market Share by Type, 2020
Figure 9: Global Biologics and Biosimilars Revenue Market Share by Type, 2020
Figure 10: Biologics and Biosimilars in Tumor
Figure 11: Global Biologics and Biosimilars Market: Tumor 2016-2021
Figure 12: Biologics and Biosimilars in Diabetes
Figure 13: Global Biologics and Biosimilars Market: Diabetes 2016-2021
Figure 14: Global Biologics and Biosimilars Sales Market Share by Application, 2020
Figure 15: Global Biologics and Biosimilars Revenue Market Share by Application, 2020
Figure 16: Global Biologics and Biosimilars Sales Market Share by Region 2016-2021
Figure 17: Global Biologics and Biosimilars Revenue Market Share by Region 2016-2021
Figure 18: North America Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 19: North America Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 20: Europe Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 21: Europe Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 22: Asia Pacific Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 23: Asia Pacific Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 24: South America Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 25: South America Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 26: Middle East and Africa Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 27: Middle East and Africa Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 28: North America Biologics and Biosimilars Sales Market Share by Country, 2020
Figure 29: North America Biologics and Biosimilars Revenue Market Share by Country, 2020
Figure 30: United States Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 31: United States Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 32: Canada Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 33: Canada Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 34: Mexico Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 35: Mexico Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 36: Europe Biologics and Biosimilars Sales Market Share by Country, 2020
Figure 37: Europe Biologics and Biosimilars Revenue Market Share by Country, 2020
Figure 38: Germany Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 39: Germany Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 40: France Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 41: France Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 42: UK Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 43: UK Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 44: Italy Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 45: Italy Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 46: Russia Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 46: Russia Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 47: Spain Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 48: Spain Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 49: Asia Pacific Biologics and Biosimilars Sales Market Share by Country, 2020
Figure 50: Asia Pacific Biologics and Biosimilars Revenue Market Share by Country, 2020
Figure 51: China Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 52: China Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 53: Japan Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 54: Japan Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 55: Korea Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 56: Korea Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 57: Southeast Asia Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 58: Southeast Asia Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 59: India Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 60: India Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 61: Australia Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 62: Australia Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 63: South America Biologics and Biosimilars Sales Market Share by Country, 2020
Figure 64: South America Biologics and Biosimilars Revenue Market Share by Country, 2020
Figure 65: Brazil Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 66: Brazil Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 67: Argentina Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 68: Argentina Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 69: Colombia Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 70: Colombia Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 71: Middle East and Africa Biologics and Biosimilars Sales Market Share by Country, 2020
Figure 72: Middle East and Africa Biologics and Biosimilars Revenue Market Share by Country, 2020
Figure 73: Turkey Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 74: Turkey Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 75: Saudi Arabia Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 76: Saudi Arabia Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 77: South Africa Biologics and Biosimilars Sales (K Units) Status 2016-2021
Figure 78: South Africa Biologics and Biosimilars Revenue (Million USD) Status 2016-2021
Figure 79: Sanofi-Aventis Biologics and Biosimilars Revenue Market Share Globally (2019-2021)
Figure 80: Roche Biologics and Biosimilars Revenue Market Share Globally (2019-2021)
Figure 81: Pfizer Biologics and Biosimilars Revenue Market Share Globally (2019-2021)
Figure 82: Novo Nordisk Biologics and Biosimilars Revenue Market Share Globally (2019-2021)
Figure 83: Novartis Biologics and Biosimilars Revenue Market Share Globally (2019-2021)
Figure 84: Merck Biologics and Biosimilars Revenue Market Share Globally (2019-2021)
Figure 85: Johnson & Johnson Biologics and Biosimilars Revenue Market Share Globally (2019-2021)
Figure 86: Innovent Biologics and Biosimilars Revenue Market Share Globally (2019-2021)
Figure 87: Gelgen Biologics and Biosimilars Revenue Market Share Globally (2019-2021)
Figure 88: Ganlee Biologics and Biosimilars Revenue Market Share Globally (2019-2021)
Figure 89: Global Biologics and Biosimilars Sales (K Units) Forecast (2022-2027)
Figure 90: Global Biologics and Biosimilars Sales (K Units) Forecast (2022-2027)


Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets